Future prospect of “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”

doi:10.3748/wjg.v28.i20.2248

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 20

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6762)

All Articles published online

The chart showing PDF series, WORD series, HTML series.

Item

Count

PDF

356

WORD

116

HTML

2611

Sum=3083

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

369

Download

940

Sum=1309

Publishing Process of This Article

Item

Count

Browse

642

Download

1728

Sum=2370

May 28, 2022 (publication date) through Feb 13, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Letter to the Editor

World J Gastroenterol. May 28, 2022; 28(20): 2248-2250
Published online May 28, 2022. doi: 10.3748/wjg.v28.i20.2248

Future prospect of “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”

Yong-Bo Kang, Yue Cai

Yong-Bo Kang, Yue Cai, Department of Microbiology and Immunology, School of Basic Medical Sciences, Shanxi Medical University, Jinzhong 030600, Shanxi Province, China

Author contributions: Kang YB and Cai Y wrote the letter and conceived the manuscript; Kang YB supervised the manuscript drafting and reviewed the literature data; and all authors contributed important intellectual content during manuscript drafting or revision.

Conflict-of-interest statement: There is no conflict to declare.

Corresponding author: Yong-Bo Kang, PhD, Associate Professor, Department of Microbiology and Immunology, School of Basic Medical Sciences, Shanxi Medical University, Wenhua Street, Jinzhong 030600, Shanxi Province, China. 657151276@qq.com

Received: December 10, 2021
Peer-review started: December 10, 2021
First decision: January 8, 2022
Revised: January 14, 2021
Accepted: April 24, 2022
Article in press: April 24, 2022
Published online: May 28, 2022
Processing time: 168 Days and 4.8 Hours

Abstract

Recently, we read the article “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients” with interest, and it is preliminary suggested that gut microbiota is closely related to therapeutic effect of nivolumab. Based on the meaningful results of this article, several valuable research directions are proposed to enhance the therapeutic effect of immune checkpoint inhibitors on advanced hepatocellular carcinoma.

Keywords: Gut microbiome; Immunotherapy; Immune checkpoint inhibitor resistance; Probiotics; Faecal microbiota transplantation; Hepatocellular carcinoma; Prognosis

Core Tip: We read the article “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients” with interest, and it is preliminary suggested that the gut microbiota is closely related to therapeutic effect of nivolumab. Future research should pay attention to the relationship between the gut microbiota and therapeutic effect of immune checkpoint inhibitors (ICIs) on advanced hepatocellular carcinoma and the way of regulating the gut microbiota to improve the therapeutic effect of ICIs.